Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors

NCT04683939 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04683939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04683939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Terminated
Start date
January 18, 2022
Completion date
July 24, 2023
Enrollment
13 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, cholangiocarcinoma, esophageal adenocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, metastatic cancer, pancreatic cancer, solid tumor